Become Affiliate

PepFlow

Download

The Tiny Bioregulator

Pinealon

Pinealon is the Glu-Asp-Arg (EDR) tripeptide studied in cell and animal models of neuronal stress and aging.

Brain healthNeuroaging biology
TierE
EvidenceLimited
SafetyLimited Data
FDA statusNot Approved
Last reviewed October 25, 2026 37 citations How to read these labels

What is Pinealon?

Pinealon is Glu-Asp-Arg (EDR), a short tripeptide in the peptide-bioregulator literature. Cell and animal studies examine neuronal stress, aging, and signaling.[20][4][5]

Its appeal comes from the small size and bioregulator tradition.[4][9][16]

Pinealon differs from Epithalon/Epitalon in its sequence and evidence base.[20][9]

What Pinealon is investigated for

Pinealon evidence is grouped by practical use case and oral route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Cognitive clarity and brain aging support

Oral

28%Limited

Cognition claims are indirect preclinical biology rather than nootropic certainty.[9][4][20][21]

Human evidence

Human memory or mental-clarity benefits have not been established for Pinealon.[6][8][12][13]

Animal / mechanistic evidence

Short-peptide aging literature and nuclear/DNA interaction work provide indirect plausibility for brain-aging claims.[9][4][20][21]

Neuroprotection

Oral

26%Limited

Neuroprotection remains an early mechanistic claim.[9][4][20][21]

Human evidence

Human neuroprotective benefits have not been established for Pinealon.[6][8][12][13]

Animal / mechanistic evidence

The neuroprotection rationale is inferred from short-peptide aging, cellular signaling, and DNA-interaction studies.[9][4][20][21]

Melatonin and pineal regulation

Oral

24%Limited

Melatonin and pineal-support claims remain preclinical and separate from proven sleep therapy.[9][4][20][21]

Human evidence

Human sleep or melatonin-regulation benefits have not been established for Pinealon.[6][8][12][13][21]

Animal / mechanistic evidence

Organotypic pineal-cell culture and animal illumination-regimen work support a pineal-axis hypothesis.[9][4][20][21]

Cellular aging and longevity support

Oral

22%Limited

Longevity support remains an animal and mechanistic hypothesis.[9][4][20][21]

Human evidence

Human lifespan extension or disease prevention has not been established for Pinealon.[6][12][13]

Animal / mechanistic evidence

Animal and short-peptide aging publications support a geroprotective hypothesis under experimental conditions.[9][4][20][21]

Evidence snapshot

12%

Human evidence

Insufficient

Human evidence is limited, with no reliable independent treatment benefit established.[6][8][12][13]

20%

Animal / preclinical

Limited

Animal and mechanistic bioregulator literature supports neuroprotection plausibility, but translation remains uncertain.[1][2][3][4][5][11][14][17][18][19]

30%

Mechanism support

Limited

Pinealon is discussed as a short peptide that may influence gene expression and neuronal stress responses. That mechanism is plausible but not enough to establish cognitive or longevity outcomes.[9][4][20][21]

Forms & administration

Pinealon is tracked as an oral short-peptide product. Oral peptide identity, formulation, and market category vary, so protocol context stays product-specific.[22][9][4]

Oral

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Oral protocols use 1-2 mg per day. Injectable protocols use about 1 mg per dose.[22][9][4]

Frequency

Oral and injectable protocols are once daily.[22][9][4]

Timing Considerations

Morning is the usual timing.[22][9][4]

Cycle Length

Oral cycles run 4-8 weeks. Injectable cycles run about 20 days.[22][9][4]

What to expect

First week

Oral Pinealon use may feel like changes in sleep-wake rhythm, morning energy, concentration, or mental fatigue.[9][4][20][21][22]

Weeks 4-8

Oral cognition-oriented effects may appear as steadier memory routines, daily energy, mood, or sleep regularity.[9][4][20][21][22]

After stopping

Perceived cognition, energy, or sleep-rhythm changes may drift back toward baseline after oral Pinealon use ends.[9][4][20][21][22]

Safety profile

Pinealon safety is an oral neuroactive-peptide question, with sleep, mood, product quality, pregnancy, and repeated cycles driving caution.[9][4][20][21]

Cautions

What we don't know

Pharmacokinetics, interactions, reproductive safety, and long-term repeated-cycle effects remain unclear.[9][4][20][21]

Who Pinealon is not for

Route-specific avoid and medical-review notes:

  • Pregnancy or breastfeeding

    Pregnancy or breastfeeding warrants medical review or avoidance for Pinealon.[9][4][20][21]

  • Unstable neurologic or psychiatric symptoms

    Unstable neurologic or psychiatric symptoms warrants medical review or avoidance for Pinealon.[9][4][20][21]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

  • Sleep aids / sedatives

    Melatonin, antihistamine sleep aids, benzodiazepines, or alcohol can compound grogginess or dream changes; this is a theoretical neuroactive caution.[9][4][20][21]

  • Stimulants / nootropics

    Stimulants, high-caffeine products, or nootropic stacks can counter sleep effects and confound cognitive tracking; this is a theoretical neuroactive caution.[9][4][20][21]

  • Psychiatric medications

    Antidepressants, antipsychotics, or mood stabilizers can make mood, sleep, or cognition changes harder to attribute; this is a theoretical neuroactive caution.[9][4][20][21]

How it works

Pinealon is a short Glu-Asp-Arg peptide discussed around gene expression, nuclear access, DNA interaction, and neuronal or pineal-cell stress responses. The practical question is whether a very small peptide can shift cell activity enough to matter for aging or cognition.[9][4][20][21]

Oral delivery is the weak link for interpretation. A peptide has to survive product handling and digestion, reach relevant tissue, and produce meaningful exposure before cell-culture or animal mechanisms can support a human longevity or cognitive-performance claim. The mechanism remains background biology, not a protocol-level claim.[9][4][20][21]

Research gaps & open questions

What the current literature has not yet settled about Pinealon:

01

Modern randomized trials need to show whether Pinealon meaningfully improves memory, attention, sleep, or day-to-day cognitive function in people.[9][4][20][21]

02

Different oral tablets, capsules, and peptide formulations need studies showing how much Pinealon is absorbed and how long it lasts.[9][4][20][21]

03

Long-term studies need to determine whether repeated Pinealon cycles remain safe and whether benefits or harms accumulate.[9][4][20][21]

Common questions

Is Pinealon FDA-approved?

No. Pinealon is not FDA-approved in the U.S. for oral drug use, and supplement or research-market availability is not FDA approval.[22][23][9][4]

Is Pinealon the same as Epithalon?

No. Pinealon is Glu-Asp-Arg (EDR), while Epithalon/Epitalon is associated with Ala-Glu-Asp-Gly (AEDG). Their identities and evidence should not be merged.[20][9]

Does Pinealon improve memory?

Not proven. A reliable improvement in human memory has not been established.[6][8][12][13]

Myths & misconceptions

Myth

A three-amino-acid peptide is automatically safe.

Reality

Small size does not replace product-quality, route, and human safety evidence.[9][4][20][21]

Myth

Bioregulator status proves anti-aging benefit.

Reality

Bioregulator framing is a hypothesis and tradition, not a clinical endpoint.[9][4][20][21]

History & discovery

Pinealon sits in the short-peptide bioregulator tradition, where small tissue-associated peptides were studied for aging, gene-expression, and neuroendocrine effects. Its public story comes from that gerontology literature. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty.[9][4][20][21]

Reviews and animal work placed Pinealon near peptide-aging and illumination-regimen studies. That origin explains longevity-market interest, but it does not establish oral human cognitive benefit.[9][4][20][21]

Fluorescent-peptide and pineal-cell culture studies shifted attention toward nuclear entry, DNA interaction, and signaling molecules. Those findings shaped mechanism claims while leaving route and outcome questions open.[9][4][20][21]

Published research37 citations

Pinealon research focuses on neuronal stress, cognition and age-related signaling. Clinical evidence remains limited, with no established independent cognitive or longevity benefit.[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Stay consistent with your focus and well-being goals.

Use PepFlow to record your Pinealon protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00